

30 January 2013

ASX ANNOUNCEMENT

APPENDIX 4C - QUARTERLY CASH FLOW

Analytica Limited (the Company) presents its Appendix 4C for the quarter ended December 2012.

The Company held cash reserves at the end of the period of \$609,000.

Research and development expenditure (\$130k), staff costs (\$158k), marketing expenses (\$38k) and general overheads (\$37k) accounted for the bulk of the operating cash flows for the quarter.

The Company continues to have a line of credit of \$400,000 to ensure adequate funding of the Company.

The securing of distribution partner CBS Médica Científica (CBS) for entry into Brazil, Latin America's largest market, with the signing of a letter of intent was a significant milestone for the marketing of Analytica's burette technology. Working with South-South Capital Partners, Analytica will be conducting product acceptance training in Sao Paulo in mid February, to facilitate trials at local hospitals as part of the market entry process. Legal documentation to formalise the relationship will follow these trials. To reduce time to market, CBS have commenced the process of gaining regulatory approval.

As previously advised we are in a position to supply burettes from our FDA approved production facility for the trials.

Materials orders have been placed to ensure we are in a position to supply stock to CBS in July 2013, on the assumption of successful trials.

Partnering with CBS, one of the largest participants in Brazilian medical devices and supplies distribution, presents huge opportunities for Analytica in a market of 190 million people. A strong health system, backed by a competitive private insurance industry makes Brazil a logical beachhead for the expansion into the rest of Latin America.

For, and on behalf of the board,

Dr Michael Monsour

Chairman, Board of Directors

Analytica Limited (ASX:ALT) is an Australian company dedicated to the design, development and supply of a range of Class I and IIa medical devices.

CBS Médica Científica (CBS) is one of the largest participants in the medical devices and supplies. CBS Med remains a family owned company after four decades of operation. With over 200 employees and contractors CBS Med has a national footprint and is a multi award winning enterprise for the distribution of 3M medical products. With sales turnover in excess of US\$100, CBS Med are projecting 30% YoY growth in 2013, reflecting their market position and the potential for growth in the health sector in Brazil. More information about CBS Med can be found at their website: www.cbsmed.com.br



Appendix 4C

*Quarterly report
for entities admitted
on the basis of commitments*

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

31 December 2012

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (6 months) \$A'000
1.1 Receipts from customers		
1.2 Payments for		
(a) staff costs	(158)	(303)
(b) advertising and marketing	(38)	(38)
(c) research and development	(130)	(323)
(d) leased assets	-	-
(e) other working capital	(37)	(126)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	11	23
1.5 Interest and other costs of finance paid	(1)	(1)
1.6 Income taxes paid	-	-
1.7 Other-		
(a) Net sales income	-	-
(b) R & D Tax Concession	-	158
(c) Royalty Income	7	7
Net operating cash flows	(346)	(603)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

		Current quarter \$A'000	Year to date (6 months) \$A'000
1.8	Net operating cash flows (carried forward)	(346)	(603)
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	(1)	(5)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (purchase of Convertible Notes)	-	-
	Net investing cash flows	(1)	(5)
1.14	Total operating and investing cash flows	(347)	(608)
Cash flows related to financing activities			
1.15	Proceeds from issues of shares	-	4
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings:	-	-
1.19	Dividends paid	-	-
1.20	Other Creditors (costs of fund raising)	-	-
	Net financing cash flows	-	4
	Net increase (decrease) in cash held	(347)	(604)
1.21	Cash at beginning of quarter/year to date	956	1213
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	Cash at end of quarter	609	609

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	48
1.25	Aggregate amount of loans to the parties included in item 1.11	13

1.26 Explanation necessary for an understanding of the transactions

Payment of director's fees and compulsory superannuation.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	400	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	609	956
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	609	956

Acquisitions and disposals of business entities

	Acquisitions	Disposals
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that [information is not required because of note 2](#)) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: **ORIGINAL SIGNED**

Date: **30 Jan 2013**

Print name: **Bryan Dulhunty**

+ See chapter 19 for defined terms.